Overview

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Status:
NOT_YET_RECRUITING

Trial end date:
2032-12-01

Target enrollment:

Participant gender:

Summary

Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance. RT, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2; Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.

Phase:

PHASE2

Details

Lead Sponsor:

Stephen Shiao

Collaborators:

Incyte Corporation
Merck Sharp & Dohme LLC

Treatments:

axatilimab
pembrolizumab
Radiotherapy